Distinct and convergent consequences of splice factor mutations in myelodysplastic syndromes
暂无分享,去创建一个
M. Cazzola | S. Ogawa | T. Haferlach | H. Koeffler | Henry Yang | L. Malcovati | M. Meggendorfer | V. Madan | Jia Li | W. W. Teoh | Lin Han | Siqin Zhou | Weoi Woon Teoh
[1] S. Shen,et al. The genetics and clinical characteristics of children morphologically diagnosed as acute promyelocytic leukemia , 2018, Leukemia.
[2] A. Gavin,et al. Impact of spliceosome mutations on RNA splicing in myelodysplasia: dysregulated genes/pathways and clinical associations. , 2018, Blood.
[3] M. Cazzola,et al. Aberrant splicing and defective mRNA production induced by somatic spliceosome mutations in myelodysplasia , 2018, Nature Communications.
[4] G. Stefani,et al. SRSF2 mutations drive oncogenesis by activating a global program of aberrant alternative splicing in hematopoietic cells , 2018, Leukemia.
[5] S. Ogawa,et al. Physiological Srsf2 P95H expression causes impaired hematopoietic stem cell functions and aberrant RNA splicing in mice. , 2018, Blood.
[6] C. Haferlach,et al. Molecular characterization of EZH2 mutant patients with myelodysplastic/myeloproliferative neoplasms , 2017, Leukemia.
[7] M. Cazzola,et al. The U2AF1S34F mutation induces lineage-specific splicing alterations in myelodysplastic syndromes , 2017, The Journal of clinical investigation.
[8] Christopher M. DeBoever,et al. Distinct splicing signatures affect converged pathways in myelodysplastic syndrome patients carrying mutations in different splicing regulators , 2016, RNA.
[9] Michelle C. Chen,et al. Physiologic Expression of Sf3b1(K700E) Causes Impaired Erythropoiesis, Aberrant Splicing, and Sensitivity to Therapeutic Spliceosome Modulation. , 2016, Cancer cell.
[10] D. Kent,et al. Hemopoietic-specific Sf3b1-K700E knock-in mice display the splicing defect seen in human MDS but develop anemia without ring sideroblasts , 2016, Leukemia.
[11] S. Miyano,et al. Comprehensive mutational analysis of primary and relapse acute promyelocytic leukemia , 2016, Leukemia.
[12] S. Roman-Roman,et al. Cancer-associated SF3B1 mutations affect alternative splicing by promoting alternative branchpoint usage , 2016, Nature Communications.
[13] A. Tefferi,et al. Myelodysplastic syndromes: Contemporary review and how we treat , 2016, American journal of hematology.
[14] M. Warmuth,et al. Cancer-Associated SF3B1 Hotspot Mutations Induce Cryptic 3' Splice Site Selection through Use of a Different Branch Point. , 2015, Cell reports.
[15] Alexander Dobin,et al. Mapping RNA‐seq Reads with STAR , 2015, Current protocols in bioinformatics.
[16] Alexander V Penson,et al. Disease-associated mutation in SRSF2 misregulates splicing by altering RNA-binding affinities , 2015, Proceedings of the National Academy of Sciences.
[17] Xiang-Dong Fu,et al. SRSF2 Is Essential for Hematopoiesis, and Its Myelodysplastic Syndrome-Related Mutations Dysregulate Alternative Pre-mRNA Splicing , 2015, Molecular and Cellular Biology.
[18] R. Fulton,et al. Mutant U2AF1 Expression Alters Hematopoiesis and Pre-mRNA Splicing In Vivo. , 2015, Cancer cell.
[19] H. Deeg,et al. SRSF2 Mutations Contribute to Myelodysplasia by Mutant-Specific Effects on Exon Recognition. , 2015, Cancer cell.
[20] R. Reed,et al. Premature termination codons are recognized in the nucleus in a reading-frame-dependent manner , 2015, Cell Discovery.
[21] J. Gécz,et al. La FAM fatale: USP9X in development and disease , 2015, Cellular and Molecular Life Sciences.
[22] S. Miyano,et al. Aberrant splicing of U12-type introns is the hallmark of ZRSR2 mutant myelodysplastic syndrome , 2014, Nature Communications.
[23] M Cazzola,et al. Disruption of SF3B1 results in deregulated expression and splicing of key genes and pathways in myelodysplastic syndrome hematopoietic stem and progenitor cells , 2014, Leukemia.
[24] L. Ding,et al. U2AF1 Mutations Alter Sequence Specificity of pre-mRNA Binding and Splicing , 2014, Leukemia.
[25] Philip Bradley,et al. U2AF1 mutations alter splice site recognition in hematological malignancies , 2014, bioRxiv.
[26] M. Stratton,et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. , 2013, Blood.
[27] H. Aburatani,et al. Concurrent loss of Ezh2 and Tet2 cooperates in the pathogenesis of myelodysplastic disorders , 2013, The Journal of experimental medicine.
[28] C Haferlach,et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes , 2013, Leukemia.
[29] J. Maciejewski,et al. Patterns of missplicing due to somatic U2AF1 mutations in myeloid neoplasms. , 2013, Blood.
[30] Wei Shi,et al. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features , 2013, Bioinform..
[31] A. Lane,et al. Putative RNA-splicing gene LUC7L2 on 7q34 represents a candidate gene in pathogenesis of myeloid malignancies , 2013, Blood Cancer Journal.
[32] B. Ko,et al. The clinical implication of SRSF2 mutation in patients with myelodysplastic syndrome and its stability during disease evolution. , 2012, Blood.
[33] S. Ogawa,et al. SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML). , 2012, Blood.
[34] O. Abdel-Wahab,et al. The role of mutations in epigenetic regulators in myeloid malignancies , 2012, Nature Reviews Cancer.
[35] Xiaomei Ma. Epidemiology of myelodysplastic syndromes. , 2012, The American journal of medicine.
[36] Benjamin E. Gross,et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.
[37] Michael Heuser,et al. Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes. , 2012, Blood.
[38] A. Jankowska,et al. Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis. , 2012, Blood.
[39] Claude Preudhomme,et al. Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes. , 2012, Blood.
[40] Franco Locatelli,et al. Spliceosomal gene aberrations are rare, coexist with oncogenic mutations, and are unlikely to exert a driver effect in childhood MDS and JMML. , 2012, Blood.
[41] S. Sugano,et al. Frequent pathway mutations of splicing machinery in myelodysplasia , 2011, Nature.
[42] J. Tamburini,et al. LKB1/AMPK/mTOR signaling pathway in hematological malignancies: From metabolism to cancer cell biology , 2011, Cell cycle.
[43] M. Kondo,et al. Role of Ras/Raf/MEK/ERK signaling in physiological hematopoiesis and leukemia development , 2011, Immunologic research.
[44] B. Viollet,et al. The LKB1/AMPK signaling pathway has tumor suppressor activity in acute myeloid leukemia through the repression of mTOR-dependent oncogenic mRNA translation. , 2010, Blood.
[45] R. Kuiper,et al. Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes , 2010, Nature Genetics.
[46] H. Drexler,et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders , 2010, Nature Genetics.
[47] P. Nguyen,et al. Myelodysplastic syndromes , 2009, Nature Reviews Disease Primers.
[48] David Komander,et al. Breaking the chains: structure and function of the deubiquitinases , 2009, Nature Reviews Molecular Cell Biology.
[49] D. Johnson,et al. Signal transduction pathways that contribute to myeloid differentiation , 2007, Leukemia.
[50] Pablo Tamayo,et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[51] H. Kantarjian,et al. Unraveling Myelodysplastic Syndromes: Current Knowledge and Future Directions , 2015, Current Oncology Reports.
[52] David P Steensma,et al. Myelodysplastic Syndromes: Diagnosis and Treatment. , 2015, Mayo Clinic proceedings.
[53] J. Bennett,et al. The myelodysplastic syndromes: diagnosis and treatment. , 2006, Mayo Clinic proceedings.
[54] James Stévenin,et al. Broad specificity of SR (serine/arginine) proteins in the regulation of alternative splicing of pre-messenger RNA. , 2004, Progress in nucleic acid research and molecular biology.